source
- Inhibrx reports 44% response rate when paired with Keytruda in head-and-neck cancer Phase 2 trialInhibrx Biosciences said its experimental agent INBRX-106 boosted the activity of Merck's Keytruda in a Phase 2 study of a head-and-neck cancer. The combination achieved a 44% overall response rate…
- Dr. Silbermann highlights trial design priorities for multiple myeloma, from supportive care to diverse enrollmentDr. Rebecca Silbermann, an associate professor at Oregon Health & Science University, outlined key considerations for designing multiple myeloma clinical trials. She stressed the importance of alig…